Vanda Pharmaceuticals Stock Revenue

VNDA Stock  USD 5.09  0.15  3.04%   
Vanda Pharmaceuticals fundamentals help investors to digest information that contributes to Vanda Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vanda Stock. The fundamental analysis module provides a way to measure Vanda Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vanda Pharmaceuticals stock.
Last ReportedProjected for Next Year
Total Revenue192.6 M137 M
At present, Vanda Pharmaceuticals' Cost Of Revenue is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.03, whereas Current Deferred Revenue is projected to grow to (5 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vanda Pharmaceuticals Company Revenue Analysis

Vanda Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Vanda Pharmaceuticals Revenue

    
  192.64 M  
Most of Vanda Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vanda Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Historical and Projected quarterly revenue of Vanda

Projected quarterly revenue analysis of Vanda Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Vanda Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Vanda Pharmaceuticals' stock price.

Vanda Revenue Driver Correlations

Understanding the fundamental principles of building solid financial models for Vanda Pharmaceuticals is extremely important. It helps to project a fair market value of Vanda Stock properly, considering its historical fundamentals such as Revenue. Since Vanda Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vanda Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vanda Pharmaceuticals' interrelated accounts and indicators.

Vanda Revenue Historical Pattern

Today, most investors in Vanda Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vanda Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vanda Pharmaceuticals revenue as a starting point in their analysis.
   Vanda Pharmaceuticals Revenue   
       Timeline  
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Vanda Current Deferred Revenue

Current Deferred Revenue

(4.97 Million)

At present, Vanda Pharmaceuticals' Current Deferred Revenue is projected to decrease significantly based on the last few years of reporting.
Based on the latest financial disclosure, Vanda Pharmaceuticals reported 192.64 M of revenue. This is 97.47% lower than that of the Biotechnology sector and 74.07% lower than that of the Health Care industry. The revenue for all United States stocks is 97.96% higher than that of the company.

Vanda Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vanda Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vanda Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vanda Pharmaceuticals by comparing valuation metrics of similar companies.
Vanda Pharmaceuticals is currently under evaluation in revenue category among its peers.

Vanda Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Vanda Pharmaceuticals from analyzing Vanda Pharmaceuticals' financial statements. These drivers represent accounts that assess Vanda Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vanda Pharmaceuticals' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap872.0M715.2M871.6M417.3M242.1M385.7M
Enterprise Value839.4M667.8M829.5M293.4M115.7M109.9M

Vanda Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vanda Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vanda Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

Vanda Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Vanda Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vanda Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vanda Pharmaceuticals' value.
Shares
Prudential Financial Inc2024-09-30
776.8 K
Connor Clark & Lunn Inv Mgmt Ltd2024-06-30
725.4 K
Federated Hermes Inc2024-09-30
716.8 K
Charles Schwab Investment Management Inc2024-09-30
596.2 K
D. E. Shaw & Co Lp2024-09-30
559.8 K
Nuveen Asset Management, Llc2024-06-30
526.8 K
Northern Trust Corp2024-09-30
501.2 K
Bridgeway Capital Management, Llc2024-09-30
419.5 K
Krensavage Asset Management, Llc2024-09-30
414.7 K
Blackrock Inc2024-06-30
8.1 M
Renaissance Technologies Corp2024-09-30
M

Vanda Fundamentals

About Vanda Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vanda Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vanda Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vanda Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:
Check out Vanda Pharmaceuticals Piotroski F Score and Vanda Pharmaceuticals Altman Z Score analysis.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
(0.19)
Revenue Per Share
3.293
Quarterly Revenue Growth
0.228
Return On Assets
(0.04)
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.